Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation

Evaluation of the Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation in Surgeries Without Nitrous Oxide Lasting More Than 2 Hours

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01774292

Enrollment

Registered

2013-01-23

Start date

2013-01-31

Completion date

2014-11-30

Last updated

2015-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coughing, Endotracheal Cuff, Extubation, Lidocaine

Keywords

Impact of alkalized lidocaine on coughing at extubation

Brief summary

The purpose of the study is to determined whether the administration of alkalized 4% lidocaine (160 mg) in the endotracheal tube cuff is effective in diminishing the incidence of coughing at extubation in surgeries lasting more than 2 hours without the use of nitrous oxide as an anesthetic agent.

Detailed description

The diffusion of nitrous oxide inside the endotracheal cuff leads to increase pressure, pain and coughing. Studies have shown benefit of alkalized lidocaine and other mediums within the cuff with nitrous oxide. No study has yet evaluated the benefit of alkalized lidocaine in long surgeries without the use of nitrous oxide.

Interventions

PROCEDUREEndotracheal intubation with injection of liquid in the cuff

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- ASA 1,2 or 3 patients requiring general anesthesia for an elective urological or gynecological surgery predicted to last more than 2 hours

Exclusion criteria

* Patient refusal * Lidocaine allergy * Any allergies to drugs or anesthetics used during the study * Under 18 years of age * Pregnant * Previous airway surgery * Cormack 3 or 4 or anticipated difficult airway * Upper respiratory tract infection in the last month * Active respiratory disease * Chronic cough or throat pain * Gastro-esophageal reflux disease or at risk for aspiration

Design outcomes

Primary

Measure	Time frame
Coughing	24 hours after the end ofsurgery

Secondary

Measure	Time frame
Throat pain	24 hours after the end of surgery
Nausea and Vomiting	24 hours after end of surgery
Hoarseness of the voice	24 hours after end of surgery

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026